Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
US FDA says lowest dose of Novo Nordisk's weight-loss drug now available
The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available on the U.S. health regulator's website on ...
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Explainer-Who in the US Benefits From $35 Insulin?
Nearly one-third of those patients were paying $35 or far more per month in 2019, according to the latest available data from ...
Eli Lilly isn't selling as much Zepbound as expected — and the stock is sinking
Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...
Eli Lilly's weight-loss drug misses Wall Street expectations, shares tumble
Eli Lilly fell short of Wall Street sales estimates for its weight-loss and diabetes drugs on Wednesday, hit by a decrease in ...
Medscape16h
Know the Ins and Outs of Prescribing Obesity Medications in Pediatric Patients
The updated AAP clinical guidelines on obesity treatment recommend offering the full spectrum of care upon initial obesity ...
STAT8h
Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...
Backlash builds against Novo’s Catalent takeover
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...